London-based startup 199 Biotechnologies announced today that it has secured $6.5M (£5.25M) in seed funding from a group of London-based private investors focused on Longevity & Biomedical Innovation. The funding will support the development of their novel therapy that aims to reverse ageing phenotype in cells through epigenetic reprogramming, with the goal of enhancing overall healthspan and quality of life.
Founded by Boris Djordjevic, 199 Biotechnologies collaborates with scientists from various institutions, including University College London (UCL), to advance the field of biogerontology, the research into ageing. The company’s research focuses on optimising the delivery of reprogramming factors to cells, bridging the gap between laboratory discoveries and clinical applications.
199 Biotechnologies’ Scientific Advisory Board comprises experts in genetics, reprogramming and microfluidics, providing valuable guidance and insights.
Boris Djordjevic, CEO of 199 Biotechnologies, shared his optimism about the company’s progress, saying, “We are committed to deliver accessible therapies to significantly reduce the burden of ageing and extend both healthspan and maximum lifespan.”
199 Biotechnologies is a biotech firm dedicated to developing advanced solutions to reverse the ageing phenotype in cells through epigenetic reprogramming. Collaborating with scientists from renowned institutions, the company harnesses its expertise in microfluidics to accelerate the development of innovative therapies that can enhance healthspan and overall quality of life. For more information, visit 99.bio/.
